Foselutoclax
A BCL-2 inhibitor used in cancer treatment
| Foselutoclax | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Foselutoclax is a small molecule BCL-2 inhibitor that is being investigated for its potential use in the treatment of various types of cancer. It is designed to induce apoptosis in cancer cells by inhibiting the B-cell lymphoma 2 (BCL-2) protein, which is often overexpressed in cancer cells and contributes to their survival.
Mechanism of Action[edit | edit source]
Foselutoclax functions by targeting the BCL-2 protein, a key regulator of the apoptosis pathway. BCL-2 is an anti-apoptotic protein that prevents the activation of the apoptotic process, allowing cancer cells to evade programmed cell death. By inhibiting BCL-2, foselutoclax promotes the release of pro-apoptotic factors, leading to the activation of the caspase cascade and subsequent cell death.
Clinical Development[edit | edit source]
Foselutoclax is currently undergoing clinical trials to evaluate its efficacy and safety in patients with various hematological malignancies, including chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). Early-phase trials have shown promising results, with some patients experiencing significant reductions in tumor burden.
Pharmacokinetics[edit | edit source]
The pharmacokinetic profile of foselutoclax is characterized by its absorption, distribution, metabolism, and excretion properties. It is administered orally and has been shown to have a favorable bioavailability. The drug is metabolized primarily in the liver and excreted through the kidneys.
Side Effects[edit | edit source]
Common side effects of foselutoclax include nausea, fatigue, and diarrhea. More serious adverse effects can include neutropenia, thrombocytopenia, and tumor lysis syndrome, which require careful monitoring and management during treatment.
Research and Future Directions[edit | edit source]
Ongoing research is focused on optimizing the dosing regimen of foselutoclax and exploring its use in combination with other anticancer agents. Studies are also investigating its potential application in solid tumors, expanding its therapeutic scope beyond hematological cancers.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
